Immunome, Inc.
General ticker "IMNM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $813.1M (TTM average)
Immunome, Inc. follows the US Stock Market performance with the rate: 54.6%.
Estimated limits based on current volatility of 4.7%: low 17.76$, high 19.51$
Factors to consider:
- Total employees count: 55 (+48.6%) as of 2023
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: History of losses, Regulatory and compliance, Litigation risks, Integration challenges, Labor/talent shortage/retention
- Current price 53.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.93$, 13.05$]
- 2025-12-31 to 2026-12-31 estimated range: [3.44$, 9.32$]
Financial Metrics affecting the IMNM estimates:
- Negative: with PPE of -4.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.41 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: Inventory ratio change, % of -0.62 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: -14.38 < Investing cash flow per share per price, % of -13.36
- Positive: Shareholder equity ratio, % of 75.41 > 63.39
Short-term IMNM quotes
Long-term IMNM plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $14.02MM | $9.04MM |
| Operating Expenses | $36.90MM | $123.55MM | $314.84MM |
| Operating Income | $-36.90MM | $-109.53MM | $-305.80MM |
| Non-Operating Income | $0.01MM | $2.75MM | $12.87MM |
| R&D Expense | $23.27MM | $103.89MM | $281.89MM |
| Income(Loss) | $-36.90MM | $-106.78MM | $-292.93MM |
| Profit(Loss)* | $-36.90MM | $-106.81MM | $-292.96MM |
| Stockholders Equity | $16.65MM | $119.88MM | $181.16MM |
| Assets | $24.05MM | $148.54MM | $240.24MM |
| Operating Cash Flow | $-28.69MM | $-7.57MM | $-110.79MM |
| Capital expenditure | $0.25MM | $0.83MM | $53.51MM |
| Investing Cash Flow | $-0.25MM | $-30.48MM | $-85.06MM |
| Financing Cash Flow | $0.03MM | $116.41MM | $240.53MM |
| Earnings Per Share** | $-3.04 | $-5.38 | $-5.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.